Pharming Group N.V. Q1 2025 Financial Summary
Business Context and Reporting Period
This Form 6-K filing, dated May 8, 2025, presents the preliminary unaudited financial results for Pharming Group N.V. for the three months ended March 31, 2025. The company is a global biopharmaceutical firm focused on rare diseases, primarily commercializing RUCONEST® (for HAE) and Joenja® (leniolisib, for APDS). The quarter included the full consolidation of the Abliva AB acquisition, completed in March 2025.
Key Financial Metrics
- Total Revenue: US$79.1 million (up 42% year-over-year).
- Product Breakdown: RUCONEST® revenue was US$68.6 million (+49%); Joenja® revenue was US$10.5 million (+9%).
- Gross Profit: US$70.8 million (up 50%); Gross margin improved to approximately 89.5%.
- Operating Profit (Loss): Reported loss of US$7.0 million. Adjusted operating profit (excluding US$7.8 million in non-recurring Abliva acquisition costs) was US$0.8 million, compared to a US$16.3 million loss in Q1 2024.
- Net Loss: US$14.9 million (US$0.022 per share), compared to a US$12.4 million loss in Q1 2024.
- Cash Flow: Operating cash flow turned positive at US$0.2 million (vs. US$7.6 million used in Q1 2024).
- Liquidity: Cash, cash equivalents, and marketable securities totaled US$108.9 million as of March 31, 2025, down from US$169.4 million at year-end 2024 due to the Abliva acquisition.
- Debt: Convertible bonds totaled approximately US$88.4 million (US$83.8 million non-current + US$4.6 million current).
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 37% increase in RUCONEST® unit sales volume in the U.S. and an 18% volume increase for Joenja®.
- Acquisition Impact: The acquisition of Abliva AB (US$66.1 million total consideration) introduced US$7.8 million in non-recurring expenses, significantly impacting the reported operating and net loss.
- Balance Sheet: Intangible assets increased significantly to US$138.9 million (from US$61.0 million) due to the capitalization of the KL1333 asset from Abliva.
- Geographic Mix: The U.S. market accounted for 97% of RUCONEST® revenue and 90% of Joenja® revenue.
Guidance, Outlook, and Management Commentary
- 2025 Revenue Guidance: Raised to US$325 million – US$340 million (previously US$315 million – US$335 million), representing 9% to 14% growth.
- Expense Outlook: Management targets a 15% or US$10 million annual reduction in G&A expenses. Total operating expenses are expected not to exceed the prior year pre-Abliva impact, with an estimated US$30 million in Abliva-related expenses.
- Pipeline Catalysts:
- Joenja® launched in England and Wales (April 2025) following NICE approval.
- Preparation to file for U.S. FDA pediatric approval in Q3 2025.
- Second wave of recruitment started for the pivotal FALCON trial (KL1333) for mitochondrial diseases.
- Organizational Changes: CEO Fabrice Chouraqui continues to lead; CFO Jeroen Wakkerman is departing at the end of May 2025.
- Risks: Forward-looking statements are subject to risks regarding clinical trial outcomes, regulatory approvals, and the successful integration of Abliva.
Investor Verification Checklist
- Verify the sustainability of the 49% RUCONEST® revenue growth and the impact of inventory destocking normalization.
- Monitor the timeline and success of the VUS (Variant of Uncertain Significance) patient reclassification efforts for Joenja® growth in H2 2025.
- Track the progress of the FALCON clinical trial for KL1333 and the integration of Abliva AB operations.
- Confirm the appointment of a permanent successor to the CFO role following Jeroen Wakkerman's departure.
- Review the cash burn rate relative to the raised revenue guidance and the US$10 million G&A reduction target.